Zoetis Inc.
MX ˙ BMV ˙ US98978V1035
SecurityMX:ZTS / Zoetis Inc.
InstitutionRegions Financial Corp
Latest Disclosed Ownership33,859 shares
Latest Disclosed Value $ 4,002,472
Regions Financial Corp reports 30.09% decrease in ownership of ZTS / Zoetis Inc.

On May 5, 2026 - Regions Financial Corp filed a 13F-HR form disclosing ownership of 33,859 shares of Zoetis Inc. (MX:ZTS) valued at $4,002,472 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 48,431 shares of Zoetis Inc.. This represents a change in shares of -30.09% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F ZOETIS CL A 98978V103 33,859 -14,572 -30.09 4,002 -34.32 0.0260
2026-01-27 2025-12-31 13F ZOETIS CL A 98978V103 48,431 -27,123 -35.90 6,094 -44.88 0.0390
2025-11-19 2025-09-30 13F/A-1 ZOETIS CL A 98978V103 75,554 -159,365 -67.84 11,055 -69.82 0.0720
2025-11-19 2025-09-30 13F ZOETIS CL A 98978V103 75,554 -159,365 11,055 0.0636
2025-07-29 2025-06-30 13F ZOETIS CL A 98978V103 234,919 -5,015 -2.09 36,636 -7.26 0.2523
2025-05-08 2025-03-31 13F ZOETIS CL A 98978V103 239,934 1,180 0.49 39,505 1.56 0.2943
2025-02-14 2024-12-31 13F Zoetis CL A 98978V103 238,754 1,794 0.76 38,900 -15.98 0.2857
2024-11-14 2024-09-30 13F Zoetis CL A 98978V103 236,960 -443 -0.19 46,297 12.49 0.3331
2024-07-31 2024-06-30 13F Zoetis CL A 98978V103 237,403 -8,092 -3.30 41,156 -0.92 0.3129
2024-04-23 2024-03-31 13F Zoetis CL A 98978V103 245,495 -6,012 -2.39 41,540 -16.32 0.3153
2024-02-06 2023-12-31 13F Pfizer CL A 98978V103 251,507 -3,244 -1.27 49,640 12.00 0.4089
2023-11-01 2023-09-30 13F Pfizer CL A 98978V103 254,751 -3,736 -1.45 44,322 -0.43 0.3986
2023-08-09 2023-06-30 13F Pfizer CL A 98978V103 258,487 -6,498 -2.45 44,514 101,068.18 0.3846
2023-05-12 2023-03-31 13F Pfizer CL A 98978V103 264,985 7,513 2.92 44 18.92 0.3959
2023-02-06 2022-12-31 13F Pfizer CL A 98978V103 257,472 -6,287 -2.38 38 -99.91 0.3469
2022-11-03 2022-09-30 13F Pfizer CL A 98978V103 263,759 991 0.38 39,113 -13.40 0.3943
2022-07-25 2022-06-30 13F Pfizer CL A 98978V103 262,768 -9,599 -3.52 45,167 -12.07 0.4296
2022-04-25 2022-03-31 13F Pfizer CL A 98978V103 272,367 4,557 1.70 51,366 -21.40 0.4146
2022-01-31 2021-12-31 13F Pfizer CL A 98978V103 267,810 4,288 1.63 65,353 27.74 0.5095
2021-11-04 2021-09-30 13F Pfizer CL A 98978V103 263,522 -8,815 -3.24 51,160 0.80 0.4422
2021-07-27 2021-06-30 13F Pfizer CL A 98978V103 272,337 -17,999 -6.20 50,753 11.00 0.4388
2021-06-02 2021-03-31 13F Pfizer CL A 98978V103 290,336 7,553 2.67 45,722 -2.31 0.4141
2021-02-05 2020-12-31 13F Pfizer CL A 98978V103 282,783 522 0.18 46,801 0.27 0.4511
2020-10-15 2020-09-30 13F Pfizer CL A 98978V103 282,261 6,433 2.33 46,677 23.49 0.5091
2020-07-27 2020-06-30 13F Pfizer CL A 98978V103 275,828 23,233 9.20 37,799 27.15 0.4399
2020-04-29 2020-03-31 13F Pfizer CL A 98978V103 252,595 12,617 5.26 29,727 -6.40 0.3956
2020-02-03 2019-12-31 13F Pfizer CL A 98978V103 239,978 -272 -0.11 31,761 6.11 0.3332
2019-10-24 2019-09-30 13F Pfizer CL A 98978V103 240,250 -7,272 -2.94 29,933 6.56 0.3324
2019-07-19 2019-06-30 13F Pfizer CL A 98978V103 247,522 899 0.36 28,091 13.14 0.3169
2019-04-19 2019-03-31 13F Pfizer CL A 98978V103 246,623 23,755 10.66 24,828 30.23 0.2859
2019-01-28 2018-12-31 13F Pfizer CL A 98978V103 222,868 74,775 50.49 19,064 40.59 0.2383
2018-10-22 2018-09-30 13F Pfizer CL A 98978V103 148,093 103,770 234.12 13,560 259.11 0.1462
2018-07-26 2018-06-30 13F Pfizer CL A 98978V103 44,323 -3,670 -7.65 3,776 -5.79 0.0426
2018-04-18 2018-03-31 13F Pfizer CL A 98978V103 47,993 659 1.39 4,008 17.54 0.0450
2018-01-18 2017-12-31 13F Pfizer CL A 98978V103 47,334 1,619 3.54 3,410 16.98 0.0369
2017-10-23 2017-09-30 13F ZOETIS COMMON STOCK 98978V103 45,715 1,764 4.01 2,915 6.31 0.0331
2017-07-31 2017-06-30 13F ZOETIS COMMON STOCK 98978V103 43,951 40,027 1,020.06 2,742 1,205.71 0.0322
2017-05-02 2017-03-31 13F ZOETIS COMMON STOCK 98978V103 3,924 105 2.75 210 2.94 0.0025
2017-02-03 2016-12-31 13F ZOETIS COMMON STOCK 98978V103 3,819 3,819 204 0.0025
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.